Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

BACKGROUND: The dipeptidyl peptidase-4 (DPP-4) inhibitors Sitagliptin and Vildagliptin lower blood glucose by augmenting endogenous levels of glucagon-like peptide-1 (GLP-1), an incretin which also confers cardioprotection. As such, we hypothesized that treatment with DPP-4 inhibitors are also cardi...

詳細記述

保存先:
書誌詳細
主要な著者: Hausenloy, Derek J, Whittington, Hannah J, Wynne, Abigail M, Begum, Shah S, Theodorou, Louise, Riksen, Niels, Mocanu, Mihaela M, Yellon, Derek M
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2013
主題:
Original Investigation
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815626/
https://ncbi.nlm.nih.gov/pubmed/24148218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2840-12-154
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料